- ‘We’re moving quickly’: Startup bags rare disease drug as Thiel-backed CEO eyes $50M fundraiseA rare disease startup with a mission to repurpose proven drugs has licensed a Chinese formulation of a well-known medicine and set its sights on a $50 million fundraise.Fierce Biotech · 3d ago↗ source
- Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesityWith PolyPeptide manufacturing peptides such as GLP-1 medicines, Samsung Biologics has identified the deal as a way to tap into fast-growing demand for obesity drug production services.BioSpace · 3d ago↗ source
- Indian generic drugmaker gets FDA warning over clinical study consentIndian generic drugmaker Alembic Pharmaceuticals has been hit with an FDA warning letter after failing to get informed consent from patients for a clinical study. In a breakaway from typical FDA…